ResMed Announces Retirement of Chief Administrative Officer and General Counsel David Pendarvis

RESMED INC

David Pendarvis, global general counsel and chief administrative officer, will retire effective June 30, 2023, after over 20 years at ResMed.
Pendarvis will serve as a consultant from July 1 to December 31, 2023, at a rate of $10,000 per month.
Amy Wakeham has been appointed Chief Communications and Investor Relations Officer, effective April 1, 2023, and will join the executive leadership team.
ResMed will conduct an internal search for a successor global general counsel and secretary.
Pendarvis will remain eligible for a short-term incentive cash payment for fiscal year 2023 based on continued employment through June 30.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

David Pendarvis

global general counsel, chief administrative officer, and secretary

RMD · RESMED INC

Effective: 2023-06-30
Filed: March 30, 2023, 7:59 PM ET

On March 29, 2023, David Pendarvis, our global general counsel, chief administrative officer, and secretary, notified us that he intends to retire, effective June 30, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David Pendarvis departed as global general counsel, chief administrative officer, and secretary at RESMED INC.

Action: retire
Role: global general counsel, chief administrative officer, and secretary

Exact text from the filing

On March 29, 2023, David Pendarvis, our global general counsel, chief administrative officer, and secretary, notified us that he intends to retire, effective June 30, 2023.

View on SEC.gov

RESMED INC filing history →

Source: SEC EDGAR

accession 0001193125-23-085659

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.